Stayble Therapeutics engages Ferghana Partners to support partnering activities
Stayble Therapeutics AB ("Stayble" or the "Company") today announces that it has entered into an agreement with the transaction advisor Ferghana Partners (“Ferghana”) ahead of the upcoming clinical results from the STA363 phase 2b study in patients with chronic back pain caused by degenerative disc disease. Provided results are positive, Ferghana will assist Stayble with international partnering activities for STA363, accelerate such activities, and supplement Stayble’s current resources.In parallel with the progress of the STA363 phase 2b study, interest from potential partners has been